Statin side effects: Weigh the benefits and risks

Source: MayoClinic.com Full Feed - Category: Consumer Health News Source Type: news

Related Links:

Publication date: March 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 2Author(s): Ian R. Barrows, Ali Ramezani, Dominic S. RajHypertension is considered as the most common risk factor for cardiovascular disease. Inflammatory processes link hypertension and cardiovascular disease, and participate in their pathophysiology. In recent years, there has been an increase in research focused on unraveling the role of inflammation and immune activation in development and maintenance of hypertension. Although inflammation is known to be associated with hypertension, whether inflammation is a cause or effect of hyp...
Source: Advances in Chronic Kidney Disease - Category: Urology & Nephrology Source Type: research
Abstract Objectives: To investigate the influence of statins on major adverse cardiovascular events (MACE) in patients with coronary microvascular dysfunction (CMVD). Participants: 23,494 patients who received coronary angiography (CAG) were included. Thrombolysis in Myocardial Infarction, Myocardial Perfusion Grading (TMPG), a useful angiographic method, was used to evaluate CMVD. Results: Using multivariate analysis, NYHA III/IV (HR, 1.44; 95% CI, 1.03-2.01; P=0.031), PCI history (HR, 3.69; 95% CI, 2.57-5.31; P
Source: Biomed Res - Category: Research Authors: Tags: Biomed Res Int Source Type: research
Researchers at the University of Ireland Galway found the proportion of the population eligible for statins rocketed from eight per cent in 1987 to 61 per cent in 2016.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
Conclusion: This study suggests that a clinically efficacious cardiovascular Chinese herbal medicine (DLP) can be successfully repurposed to treat a lung disease in pulmonary fibrosis guided by TCM theory. Our comparative study between DLP and DHP demonstrated a critical requirement of suppressing both pro-inflammatory and pro-fibrotic pathways for the treatment of pulmonary fibrosis, supporting that a multi-component prescription capable of “removing both phlegm and blood stasis” will better achieve co-protection of heart and lung in PHD. Introduction Idiopathic pulmonary fibrosis (IPF) is a chronic an...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Conclusion: In conclusion, Baishouwu extract exhibited potent effect on the development of HCC by altering TLR4/MyD88/ NF-κB signaling pathway in the sequence of hepatic inflammation-fibrosis-cancer, which provided novel insights into the mechanism of Baishouwu extract as a candidate for the pretreatment of HCC in the future. Introduction Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world and the third cause of cancer-related deaths (Jemal et al., 2011). Chronic inflammation, caused by chemical, biological and physical factors, is found to be related to certain human cancers. The effe...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Source: BMJ Comments - Category: General Medicine Source Type: forums
The ACC/AHA blood cholesterol treatment guidelines recommend statin therapy for all patients after experiencing an acute cardiovascular event. Previous analyses have shown that physicians have been slow to adopt guidelines, and many patients remain untreated or undertreated with statins after a cardiovascular event. However, reasons for this remain unknown. This analysis used EMR and patient chart data from Reliant Medical Group (Worcester, Massachusetts, USA) to evaluate physician adherence to the 2013 ACC/AHA blood cholesterol guidelines when treating patients with evidence of acute atherosclerotic cardiovascular disease...
Source: The American Journal of Cardiology - Category: Cardiology Authors: Source Type: research
In patients with type 2 diabetes and hyperlipidemia or mixed dyslipidemia on a maximally tolerated statin, treatment with evolocumab lowers low-density-lipoprotein cholesterol (LDL-C) and improves levels of other lipids, researchers say.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
Like more than half of older men, I take a cholesterol-lowering medication called a statin. Sometimes that seems a bit strange, because I don ’t have high cholesterol. My doctor prescribed it based on a formula that largely hinges on age and sex. I’m 71 and male. Those two factors alone put me in the high-risk category for […]Find jobs at  Careers by KevinMD.com.  Search thousands of physician, PA, NP, and CRNA jobs now.  Learn more.
Source: Kevin, M.D. - Medical Weblog - Category: General Medicine Authors: Tags: Conditions Cardiology Source Type: blogs
Authors: Simons LA Abstract Statin drugs reduce low-density lipoprotein (LDL)-cholesterol (LDL-C) and cardiovascular risk. Ezetimibe may be used to supplement statin therapy, or used alone in cases of statin intolerance. Statin-associated side effects do occur, especially muscle symptoms and new onset diabetes, but they do not detract from the benefits of statin therapy. Inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK9) reduce LDL-C and cardiovascular risk. Evolocumab is subsidised in Australia for patients with familial hypercholesterolaemia when LDL-C is not adequately controlled with maximum do...
Source: Medical Journal of Australia - Category: General Medicine Tags: Med J Aust Source Type: research
More News: Cholesterol | Health | Statin Therapy